Remission persisted through 104 weeks for most patients with eosinophilic granulomatosis with polyangiitis who used ...
Researchers assessed patients receiving omalizumab, dupilumab, mepolizumab, benralizumab, reslizumab or tezepelumab for asthma. Adherence was deemed intermittent based on heatmaps. SAN DIEGO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback